Pfizer meets amyloidosis rival as BridgeBio wins FDA nod for Attruby
BridgeBio Pharma (BBIO) wins FDA nod Attruby for rare heart disorder, ATTR-CM challenging Pfizer's (PFE) Vyndaqel. Read more ...
BridgeBio heart drug approved by FDA, setting up battle with Pfizer
The approval of Attruby for transthyretin amyloidosis with cardiomyopathy begins a battle for control of a lucrative market ...
STAT20h
BridgeBio wins FDA approval for heart disease drug
The Food and Drug Administration approved on Friday a new medicine from BridgeBio for patients with a progressive heart ...
The Heart of the Matter
If you or someone you love has heart failure and unresolved, seemingly unrelated symptoms such as carpal tunnel syndrome, shortness of breath, irregular heartbeat, or even lower back pain, it could be ...
New cardiac MRI technique better spots serious heart ailment
A new technology that allows doctors to quantify blood flow in the heart can improve their ability to diagnose potentially ...
Ultromics obtains Breakthrough Device FDA clearance for its Cardiac Amyloidosis screening device through the Total Product Lifecycle Advisory Program
Ultromics' EchoGo® Amyloidosis, clinical AI for echocardiography with the potential to revolutionize early detection of ...
News Medical3d
CRISPR-based therapy shown to be safe, effective for people with transthyretin amyloidosis
Results for the Phase I clinical trial, published in the New England Journal of Medicine, bring hope for people with transthyretin amyloidosis (ATTR), who have ... and slowing down the progression of ...
Study highlights physician perspectives on emerging anti-amyloid treatments for Alzheimer's disease
In a recent study, Tel Aviv Sourasky Medical Center has shed light on physician attitudes toward novel anti-amyloid ...
STAT4d
Two drugs look promising for lipoprotein(a), a common genetic risk factor for heart disease
At AHA, Phase 2 results from Eli Lilly and Silence Therapeutics are seen as signs of a "major new path" of cardiovascular ...
Pharmaceutical Technology5d
Intellia’s gene editing therapy shows early potential in rare heart condition
Intellia presented data from its Phase I study of NTLA-2001 at the 2024 American Heart Association scientific meeting in ...
BioSpace5d
Intellia’s CRISPR Gene Editor Shows Early Promise With Strong Biomarker Benefit in ATTR Amyloidosis
Analysts appear optimistic for Intellia’s gene editor nex-z, which showed a greater serum TTR reduction than Alnylam’s ...
News Medical6d
Excessive sedentary time linked to higher heart disease risk
More time spent sitting, reclining or lying down during the day may increase the risk of cardiovascular disease (CVD) and death, according to a study in JACC, the flagship journal of the American ...